Global Checkpoint Inhibitor Refractory Cancer Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,480	137 Pages	GlobalInfoResearch	April, 2025	GFSH19992015

Best Price Guarantee
Price	from $3,480
Length	137 Pages
Publisher	GlobalInfoResearch
Published Date	April, 2025
SKU	GFSH19992015

According to our (Global Info Research) latest study, the global Checkpoint Inhibitor Refractory Cancer market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report is a detailed and comprehensive analysis for global Checkpoint Inhibitor Refractory Cancer market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Checkpoint Inhibitor Refractory Cancer market size and forecasts, in consumption value ($ Million), 2020-2031

Global Checkpoint Inhibitor Refractory Cancer market size and forecasts by region and country, in consumption value ($ Million), 2020-2031

Global Checkpoint Inhibitor Refractory Cancer market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031

Global Checkpoint Inhibitor Refractory Cancer market shares of main players, in revenue ($ Million), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Checkpoint Inhibitor Refractory Cancer

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Checkpoint Inhibitor Refractory Cancer market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol-Myers Squibb, AstraZeneca, Merck, Roche, Regeneron Pharmaceuticals, Bristol-Myers Squibb, Janssen Research and Development, 4D pharma, 4SC AG, OncoSec Medical, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Checkpoint Inhibitor Refractory Cancer market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors

Market segment by Application
Hodgkin Lymphoma
Kidney Cancer
Melanoma
Non-Small Cell Lung Cancer
Others

Market segment by players, this report covers
Bristol-Myers Squibb
AstraZeneca
Merck
Roche
Regeneron Pharmaceuticals
Bristol-Myers Squibb
Janssen Research and Development
4D pharma
4SC AG
OncoSec Medical
Mirati Therapeutics
Ascentage Pharma Group
ENB Therapeutics
Exicure
Eisai
Kartos Therapeutics
Exelixis
ImmunityBio

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Checkpoint Inhibitor Refractory Cancer product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Checkpoint Inhibitor Refractory Cancer, with revenue, gross margin, and global market share of Checkpoint Inhibitor Refractory Cancer from 2020 to 2025.

Chapter 3, the Checkpoint Inhibitor Refractory Cancer competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Checkpoint Inhibitor Refractory Cancer market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Checkpoint Inhibitor Refractory Cancer.

Chapter 13, to describe Checkpoint Inhibitor Refractory Cancer research findings and conclusion.

1 Market Overview: 1.1 Product Overview and Scope; 1.2 Market Estimation Caveats and Base Year; 1.3 Classification of Checkpoint Inhibitor Refractory Cancer by Type; 1.3.1 Overview: Global Checkpoint Inhibitor Refractory Cancer Market Size by Type: 2020 Versus 2024 Versus 2031; 1.3.2 Global Checkpoint Inhibitor Refractory Cancer Consumption Value Market Share by Type in 2024; 1.3.3 PD-1 Inhibitors; 1.3.4 PD-L1 Inhibitors; 1.4 Global Checkpoint Inhibitor Refractory Cancer Market by Application; 1.4.1 Overview: Global Checkpoint Inhibitor Refractory Cancer Market Size by Application: 2020 Versus 2024 Versus 2031; 1.4.2 Hodgkin Lymphoma; 1.4.3 Kidney Cancer; 1.4.4 Melanoma; 1.4.5 Non-Small Cell Lung Cancer; 1.4.6 Others; 1.5 Global Checkpoint Inhibitor Refractory Cancer Market Size & Forecast; 1.6 Global Checkpoint Inhibitor Refractory Cancer Market Size and Forecast by Region; 1.6.1 Global Checkpoint Inhibitor Refractory Cancer Market Size by Region: 2020 VS 2024 VS 2031; 1.6.2 Global Checkpoint Inhibitor Refractory Cancer Market Size by Region, (2020-2031); 1.6.3 North America Checkpoint Inhibitor Refractory Cancer Market Size and Prospect (2020-2031); 1.6.4 Europe Checkpoint Inhibitor Refractory Cancer Market Size and Prospect (2020-2031); 1.6.5 Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size and Prospect (2020-2031); 1.6.6 South America Checkpoint Inhibitor Refractory Cancer Market Size and Prospect (2020-2031); 1.6.7 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size and Prospect (2020-2031)
2 Company Profiles: 2.1 Bristol-Myers Squibb; 2.1.1 Bristol-Myers Squibb Details; 2.1.2 Bristol-Myers Squibb Major Business; 2.1.3 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.1.4 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.1.5 Bristol-Myers Squibb Recent Developments and Future Plans; 2.2 AstraZeneca; 2.2.1 AstraZeneca Details; 2.2.2 AstraZeneca Major Business; 2.2.3 AstraZeneca Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.2.4 AstraZeneca Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.2.5 AstraZeneca Recent Developments and Future Plans; 2.3 Merck; 2.3.1 Merck Details; 2.3.2 Merck Major Business; 2.3.3 Merck Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.3.4 Merck Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.3.5 Merck Recent Developments and Future Plans; 2.4 Roche; 2.4.1 Roche Details; 2.4.2 Roche Major Business; 2.4.3 Roche Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.4.4 Roche Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.4.5 Roche Recent Developments and Future Plans; 2.5 Regeneron Pharmaceuticals; 2.5.1 Regeneron Pharmaceuticals Details; 2.5.2 Regeneron Pharmaceuticals Major Business; 2.5.3 Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.5.4 Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.5.5 Regeneron Pharmaceuticals Recent Developments and Future Plans; 2.6 Bristol-Myers Squibb; 2.6.1 Bristol-Myers Squibb Details; 2.6.2 Bristol-Myers Squibb Major Business; 2.6.3 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.6.4 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.6.5 Bristol-Myers Squibb Recent Developments and Future Plans; 2.7 Janssen Research and Development; 2.7.1 Janssen Research and Development Details; 2.7.2 Janssen Research and Development Major Business; 2.7.3 Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.7.4 Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.7.5 Janssen Research and Development Recent Developments and Future Plans; 2.8 4D pharma; 2.8.1 4D pharma Details; 2.8.2 4D pharma Major Business; 2.8.3 4D pharma Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.8.4 4D pharma Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.8.5 4D pharma Recent Developments and Future Plans; 2.9 4SC AG; 2.9.1 4SC AG Details; 2.9.2 4SC AG Major Business; 2.9.3 4SC AG Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.9.4 4SC AG Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.9.5 4SC AG Recent Developments and Future Plans; 2.10 OncoSec Medical; 2.10.1 OncoSec Medical Details; 2.10.2 OncoSec Medical Major Business; 2.10.3 OncoSec Medical Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.10.4 OncoSec Medical Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.10.5 OncoSec Medical Recent Developments and Future Plans; 2.11 Mirati Therapeutics; 2.11.1 Mirati Therapeutics Details; 2.11.2 Mirati Therapeutics Major Business; 2.11.3 Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.11.4 Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.11.5 Mirati Therapeutics Recent Developments and Future Plans; 2.12 Ascentage Pharma Group; 2.12.1 Ascentage Pharma Group Details; 2.12.2 Ascentage Pharma Group Major Business; 2.12.3 Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.12.4 Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.12.5 Ascentage Pharma Group Recent Developments and Future Plans; 2.13 ENB Therapeutics; 2.13.1 ENB Therapeutics Details; 2.13.2 ENB Therapeutics Major Business; 2.13.3 ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.13.4 ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.13.5 ENB Therapeutics Recent Developments and Future Plans; 2.14 Exicure; 2.14.1 Exicure Details; 2.14.2 Exicure Major Business; 2.14.3 Exicure Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.14.4 Exicure Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.14.5 Exicure Recent Developments and Future Plans; 2.15 Eisai; 2.15.1 Eisai Details; 2.15.2 Eisai Major Business; 2.15.3 Eisai Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.15.4 Eisai Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.15.5 Eisai Recent Developments and Future Plans; 2.16 Kartos Therapeutics; 2.16.1 Kartos Therapeutics Details; 2.16.2 Kartos Therapeutics Major Business; 2.16.3 Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.16.4 Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.16.5 Kartos Therapeutics Recent Developments and Future Plans; 2.17 Exelixis; 2.17.1 Exelixis Details; 2.17.2 Exelixis Major Business; 2.17.3 Exelixis Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.17.4 Exelixis Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.17.5 Exelixis Recent Developments and Future Plans; 2.18 ImmunityBio; 2.18.1 ImmunityBio Details; 2.18.2 ImmunityBio Major Business; 2.18.3 ImmunityBio Checkpoint Inhibitor Refractory Cancer Product and Solutions; 2.18.4 ImmunityBio Checkpoint Inhibitor Refractory Cancer Revenue, Gross Margin and Market Share (2020-2025); 2.18.5 ImmunityBio Recent Developments and Future Plans
3 Market Competition, by Players: 3.1 Global Checkpoint Inhibitor Refractory Cancer Revenue and Share by Players (2020-2025); 3.2 Market Share Analysis (2024); 3.2.1 Market Share of Checkpoint Inhibitor Refractory Cancer by Company Revenue; 3.2.2 Top 3 Checkpoint Inhibitor Refractory Cancer Players Market Share in 2024; 3.2.3 Top 6 Checkpoint Inhibitor Refractory Cancer Players Market Share in 2024; 3.3 Checkpoint Inhibitor Refractory Cancer Market: Overall Company Footprint Analysis; 3.3.1 Checkpoint Inhibitor Refractory Cancer Market: Region Footprint; 3.3.2 Checkpoint Inhibitor Refractory Cancer Market: Company Product Type Footprint; 3.3.3 Checkpoint Inhibitor Refractory Cancer Market: Company Product Application Footprint; 3.4 New Market Entrants and Barriers to Market Entry; 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type: 4.1 Global Checkpoint Inhibitor Refractory Cancer Consumption Value and Market Share by Type (2020-2025); 4.2 Global Checkpoint Inhibitor Refractory Cancer Market Forecast by Type (2026-2031)
5 Market Size Segment by Application: 5.1 Global Checkpoint Inhibitor Refractory Cancer Consumption Value Market Share by Application (2020-2025); 5.2 Global Checkpoint Inhibitor Refractory Cancer Market Forecast by Application (2026-2031)
6 North America: 6.1 North America Checkpoint Inhibitor Refractory Cancer Consumption Value by Type (2020-2031); 6.2 North America Checkpoint Inhibitor Refractory Cancer Market Size by Application (2020-2031); 6.3 North America Checkpoint Inhibitor Refractory Cancer Market Size by Country; 6.3.1 North America Checkpoint Inhibitor Refractory Cancer Consumption Value by Country (2020-2031); 6.3.2 United States Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031); 6.3.3 Canada Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031); 6.3.4 Mexico Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031)
7 Europe: 7.1 Europe Checkpoint Inhibitor Refractory Cancer Consumption Value by Type (2020-2031); 7.2 Europe Checkpoint Inhibitor Refractory Cancer Consumption Value by Application (2020-2031); 7.3 Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country; 7.3.1 Europe Checkpoint Inhibitor Refractory Cancer Consumption Value by Country (2020-2031); 7.3.2 Germany Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031); 7.3.3 France Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031); 7.3.4 United Kingdom Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031); 7.3.5 Russia Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031); 7.3.6 Italy Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031)
8 Asia-Pacific: 8.1 Asia-Pacific Checkpoint Inhibitor Refractory Cancer Consumption Value by Type (2020-2031); 8.2 Asia-Pacific Checkpoint Inhibitor Refractory Cancer Consumption Value by Application (2020-2031); 8.3 Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size by Region; 8.3.1 Asia-Pacific Checkpoint Inhibitor Refractory Cancer Consumption Value by Region (2020-2031); 8.3.2 China Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031); 8.3.3 Japan Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031); 8.3.4 South Korea Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031); 8.3.5 India Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031); 8.3.6 Southeast Asia Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031); 8.3.7 Australia Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031)
9 South America: 9.1 South America Checkpoint Inhibitor Refractory Cancer Consumption Value by Type (2020-2031); 9.2 South America Checkpoint Inhibitor Refractory Cancer Consumption Value by Application (2020-2031); 9.3 South America Checkpoint Inhibitor Refractory Cancer Market Size by Country; 9.3.1 South America Checkpoint Inhibitor Refractory Cancer Consumption Value by Country (2020-2031); 9.3.2 Brazil Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031); 9.3.3 Argentina Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031)
10 Middle East & Africa: 10.1 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Consumption Value by Type (2020-2031); 10.2 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Consumption Value by Application (2020-2031); 10.3 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size by Country; 10.3.1 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Consumption Value by Country (2020-2031); 10.3.2 Turkey Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031); 10.3.3 Saudi Arabia Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031); 10.3.4 UAE Checkpoint Inhibitor Refractory Cancer Market Size and Forecast (2020-2031)
11 Market Dynamics: 11.1 Checkpoint Inhibitor Refractory Cancer Market Drivers; 11.2 Checkpoint Inhibitor Refractory Cancer Market Restraints; 11.3 Checkpoint Inhibitor Refractory Cancer Trends Analysis; 11.4 Porters Five Forces Analysis; 11.4.1 Threat of New Entrants; 11.4.2 Bargaining Power of Suppliers; 11.4.3 Bargaining Power of Buyers; 11.4.4 Threat of Substitutes; 11.4.5 Competitive Rivalry
12 Industry Chain Analysis: 12.1 Checkpoint Inhibitor Refractory Cancer Industry Chain; 12.2 Checkpoint Inhibitor Refractory Cancer Upstream Analysis; 12.3 Checkpoint Inhibitor Refractory Cancer Midstream Analysis; 12.4 Checkpoint Inhibitor Refractory Cancer Downstream Analysis
13 Research Findings and Conclusion
14 Appendix: 14.1 Methodology; 14.2 Research Process and Data Source; 14.3 Disclaimer